NS Pharma, Inc.
3 clinical trials · 3 recruiting · INDUSTRY
Trials by NS Pharma, Inc.
RECRUITINGPhase 2NCT06046222
Trial of Efficacy and Safety of NS-229 Versus Placebo in Patients With Eosinophilic Granulomatosis With Polyangiitis
This study will enroll male and female subjects who are 18 years of age or older with Eosinophilic Granulomatosis With Polyangiitis.
Sponsor: NS Pharma, Inc.Enrolling: 4520 locations
Eosinophilic Granulomatosis With PolyangiitisChurg-Strauss Syndrome
RECRUITINGPhase 1 / Phase 2NCT06053814
NS-050/NCNP-03 in Boys With DMD (Meteor50)
This is a Phase 1/2 study of Multiple-Ascending Dose (MAD) levels for 12 weeks of treatment followed by 24 weeks of open-label treatment with a selected dose of NS-050/NCNP-03...
Sponsor: NS Pharma, Inc.Enrolling: 2018 locations
Duchenne Muscular Dystrophy
RECRUITINGPhase 2NCT05996003
NS-089/NCNP-02-201 in Boys With Duchenne Muscular Dystrophy (DMD)
This is a Phase 2, open-label, multi-center, 2-part study of NS-089/NCNP-02 administered by weekly IV infusion to ambulant boys aged ≥4 to \<15 years with DMD due to mutations...
Sponsor: NS Pharma, Inc.Enrolling: 2020 locations
Duchenne Muscular DystrophyExon 44DMD